Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.

Abstract excerpt

PURPOSE: The aim of this study was to evaluate tumour response, QoL and adverse effects of erlotinib, EGFR tyrosine kinase inhibitor (TKI), as a second line therapy for patients with EGFR mutation in NSCLC, after failure of previous first-line therapy. METHODS: During the year 2010-11, 5 patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Biopsy
• Share to Carcinoma, Non-Small-Cell Lung